Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab vs Nivolumab in Previously Treated Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
NCT02785952Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Dec 2015
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ipilimumab in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 3 years. Started Dec 2015; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02785952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785952.